MX9302300A - Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos. - Google Patents

Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.

Info

Publication number
MX9302300A
MX9302300A MX9302300A MX9302300A MX9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A
Authority
MX
Mexico
Prior art keywords
preparation
treatment
prostatic hypertrophy
steroid derivatives
compound
Prior art date
Application number
MX9302300A
Other languages
English (en)
Spanish (es)
Inventor
Miroyoshi Horikoshi
Takakazu Hamada
Koichi Kojima
Hitoshi Kurata
Koki Ishibashi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9302300A publication Critical patent/MX9302300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX9302300A 1992-04-20 1993-04-20 Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos. MX9302300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9981692 1992-04-20
JP32804392 1992-12-08

Publications (1)

Publication Number Publication Date
MX9302300A true MX9302300A (es) 1994-03-31

Family

ID=26440917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302300A MX9302300A (es) 1992-04-20 1993-04-20 Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.

Country Status (25)

Country Link
US (3) US5536714A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0567271B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2514778B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0146680B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1041095C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE154937T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU656852B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2094300C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (2) CZ283791B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69311837T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0567271T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2105108T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI931765A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3024896T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1000303A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU219579B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID18576A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL105478A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9302300A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO304891B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ247449A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31052A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2114861C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW401420B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA932732B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
BR9306419A (pt) * 1992-04-30 1998-09-15 Smithkline Beecham Corp Acido 17 e 17 substituído estra 1,3,5 (10) triena-3-carboxilico
GB9224148D0 (en) * 1992-11-18 1993-01-06 Smithkline Beecham Corp Compounds
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
DE69431662T2 (de) * 1993-09-03 2003-09-18 Smithkline Beecham Corp., King Of Prussia Stabilisierte tablettenformulierung
GB9324371D0 (en) * 1993-11-26 1994-01-12 Erba Carlo Spa Side chain fluoro substituted 3-carboxysteroids
GB9411103D0 (en) * 1994-06-03 1994-07-27 Smithkline Beecham Corp Compounds
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
AU8779898A (en) * 1997-08-11 1999-03-01 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
WO2003029268A1 (en) * 2001-10-03 2003-04-10 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
AU2002361861A1 (en) * 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
EP1624876A2 (en) * 2003-04-29 2006-02-15 The Miriam Hospital Selective testicular 11beta-hsd inhibitors and methods of use thereof
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
US7604386B2 (en) * 2005-11-18 2009-10-20 Federal-Mogul World Wide, Inc Lamp assembly having a socket made from high temperature plastic
CN104208718B (zh) 2009-02-20 2017-12-29 2-Bbb医疗股份有限公司 基于谷胱甘肽的药物递送系统
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011004242A2 (en) * 2009-07-09 2011-01-13 Aurobindo Pharma Limited An improved process for the preparation of dutasteride
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Also Published As

Publication number Publication date
EP0567271B1 (en) 1997-07-02
HUT64558A (en) 1994-01-28
FI931765L (fi) 1993-10-21
TW238312B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-01-11
DE69311837T2 (de) 1998-02-12
RU95101838A (ru) 1997-01-10
KR0146680B1 (ko) 1998-08-01
GR3024896T3 (en) 1998-01-30
RU2114861C1 (ru) 1998-07-10
EP0725074A2 (en) 1996-08-07
NZ247449A (en) 1995-02-24
JP2514778B2 (ja) 1996-07-10
JPH06279487A (ja) 1994-10-04
EP0725074A3 (en) 1996-11-20
ZA932732B (en) 1993-10-28
FI931765A7 (fi) 1993-10-21
HU9301155D0 (en) 1993-07-28
NO304891B1 (no) 1999-03-01
EP0567271A3 (en) 1994-11-23
CZ283791B6 (cs) 1998-06-17
FI931765A0 (fi) 1993-04-19
US5536714A (en) 1996-07-16
CN1041095C (zh) 1998-12-09
CN1195666A (zh) 1998-10-14
US5717088A (en) 1998-02-10
CA2094300C (en) 2003-01-28
HU219579B (hu) 2001-05-28
PH31052A (en) 1998-02-03
ID18576A (id) 1998-04-23
US5760025A (en) 1998-06-02
DK0567271T3 (da) 1998-02-16
HK1000303A1 (en) 1998-02-20
CZ284206B6 (cs) 1998-09-16
NO931401D0 (no) 1993-04-16
EP0567271A2 (en) 1993-10-27
CN1083070A (zh) 1994-03-02
DE69311837D1 (de) 1997-08-07
IL105478A (en) 1998-03-10
CZ67893A3 (en) 1994-01-19
IL105478A0 (en) 1993-08-18
ES2105108T3 (es) 1997-10-16
NO931401L (no) 1993-10-21
AU656852B2 (en) 1995-02-16
KR930021654A (ko) 1993-11-22
AU3698493A (en) 1993-10-21
ATE154937T1 (de) 1997-07-15
TW401420B (en) 2000-08-11
CZ90097A3 (cs) 1998-07-15
CA2094300A1 (en) 1993-10-21
RU2097387C1 (ru) 1997-11-27

Similar Documents

Publication Publication Date Title
MX9302300A (es) Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ES2174989T3 (es) Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion.
BR0215052A (pt) Composições acaricidas e métodos
ES2019899T4 (es) Procedimiento para preparar trans-6-6(2-3(3-o 4-carboxamido-sustituido-pirrol-1-il)-alquil)-4-hidroxipiran-2-onas con actividad inhibidora de la sintesis de colesterol.
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
PA8436001A1 (es) Inhibidores de naaladasa.
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
BR9914925A (pt) Processos para reduzir o crescimento de cabelo de mamìfero, para tratar uma área de pele, e, para produzir uma composição para inibir crescimento do cabelo de mamìfero, uso de um inibidor de fosfatase alcalina, e, composição usada para inibir crescimento de cabelo de mamìfero.
AR038433A2 (es) Derivados 2-alquil-2-desoxo de parahercuamida y marcfortina
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
CO4700526A1 (es) Compuestos novedosos, la preparacion y el uso de estos
DE69733061D1 (de) Nicht-steroidale polyzyklische sulfamat-derivate, deren herstellung und deren verwendung als östron sulfatase inhibitoren
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
MX9304541A (es) Esteriodes de 17-espirometileno.
KR930702002A (ko) 아폽토시스 조정제
BR9809628A (pt) Processos para preparação de um composto e para a preparação de um aminoálcool.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
ATE323495T1 (de) Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
ES2012736A6 (es) Procedimiento para la preparacion de derivados triciclicos de 3-oxopropanonitrilo.
ES2193248T3 (es) Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea.